Effectiveness and Safety Study on Different Timing of Preventive Ileostomy Closure After Surgery for Rectal Cancer

Sponsor
Huashan Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT02665026
Collaborator
(none)
250
1
1
62.9
4

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the appropriate timing to do preventive ileostomy closure after total mesorectal excision of rectal cancer. To evaluate the effectiveness and safety of preventive ileostomy closure at different time (12 weeks / 24 weeks after radical resection of rectal carcinoma). This study was expected to demonstrate that the early preventive ileostomy closure after total mesorectal excision of rectal cancer does not increase the risk of complications.

Condition or Disease Intervention/Treatment Phase
  • Procedure: stoma closure at different times
N/A

Detailed Description

A temporary stoma may, in fact, result in reduced quality of life because of feelings of physical and mental restriction, debilitating nuisance, among other problems. Skin irritation, prolapse, and retractionare quite common after ileostomy. A high incidence of parastomal hernia, ileus, and increased salt and fluid loss has been reported, which may also contribute to greater willingness of both the surgeon and patient to close the temporary stoma as soon as possible.

Currently, it remains unclear whether stoma closure should be performed after the end of chemotherapy or during chemotherapy (12 weeks or 24 weeks after radical resection of rectal carcinoma).

The aim of this study is to assess the possible impact of stoma closure timing on postoperative results and to evaluate that the early preventive ileostomy closure after total mesorectal excision of rectal cancer does not increase the risk of complications.

Study Design

Study Type:
Interventional
Actual Enrollment :
250 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Single Center, Open, Randomized Clinical Trials, Effectiveness and Safety Study on Different Timing of Preventive Ileostomy Closure After Total Mesorectal Excision for Middle and Low Rectal Cancer
Actual Study Start Date :
Jan 4, 2016
Actual Primary Completion Date :
Mar 22, 2021
Actual Study Completion Date :
Mar 31, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: stoma closure at different times

choose different times to do stoma closure after surgery for rectal cancer

Procedure: stoma closure at different times
Early closure: stoma closure in 12 weeks after surgery for rectal cancer; Late group: stoma closure in 24 weeks after surgery for rectal cancer

Outcome Measures

Primary Outcome Measures

  1. Postoperative complication [within the first 2 weeks after surgery]

Secondary Outcome Measures

  1. Postoperative quality of life [five years]

  2. survival rate [five years]

  3. Disease-free survival [five years]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • sign the informed consent

  • postoperative pathology is rectal adenocarcinoma

  • primary middle and low rectal cancer patients (tumor distance from the anal margin is less than 10 cm)

  • underwent total mesorectal excision for rectal cancer with preventive loop ileostomy

Exclusion Criteria:
  • postoperative pathology is not rectal adenocarcinoma (rectal neuroendocrine tumor, lymphoma, etc.)

  • postoperative pathologic staging of rectal cancer is I phase, II phase

  • underwent total mesorectal excision for rectal cancer without preventive loop ileostomy

  • emergency operation for rectal cancer

  • disease progression (local recurrence or distant metastasis, etc.)

  • anastomotic stenosis

  • serious system disease, including heart dysfunction, respiratory insufficiency, liver and kidney dysfunction, serious blood diseases

  • participate in other clinical trial

  • pregnancy or perinatal woman

  • combined with other malignant tumor

  • with a history of neurological and psychiatric disorders

  • patients with abnormal bone marrow suppression after chemotherapy

Contacts and Locations

Locations

Site City State Country Postal Code
1 Huashan Hospital Affiliated to Fudan University Shanghai China 200040

Sponsors and Collaborators

  • Huashan Hospital

Investigators

  • Principal Investigator: Jianbin Xiang, doctor, Huashan Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Jianbin Xiang, professor, Huashan Hospital
ClinicalTrials.gov Identifier:
NCT02665026
Other Study ID Numbers:
  • KY2015-276
First Posted:
Jan 27, 2016
Last Update Posted:
Sep 21, 2021
Last Verified:
Sep 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 21, 2021